Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RVU120

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ryvu Therap

Drug class:

CDK19 inhibitor, CDK8 inhibitor

Related drugs:

‹

›

DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4
DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib + RVU120 Sensitive: D – Preclinical gilteritinib + RVU120 Sensitive : D	gilteritinib + RVU120 Sensitive: D – Preclinical gilteritinib + RVU120 Sensitive : D
HR negative + EGFR amplification	Triple Negative Breast Cancer	HR negative + EGFR amplification	Triple Negative Breast Cancer	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D	RVU120 Sensitive: D – Preclinical RVU120 Sensitive : D